help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willson, T. M.
Right arrow Articles by McDonnell, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willson, T. M.
Right arrow Articles by McDonnell, D. P.
Endocrinology Vol. 138, No. 9 3901-3911
Copyright © 1997 by The Endocrine Society

ARTICLES

Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone1

T. M. Willson, J. D. Norris, B. L. Wagner, I. Asplin, P. Baer, H. R. Brown, S. A. Jones, B. Henke, H. Sauls, S. Wolfe, D. C. Morris and D. P. McDonnell

Glaxo Wellcome Research and Development (T.M.W., P.B., H.R.B., S.A.J., B.H., H.S., S.W., D.M.), Research Triangle Park, North Carolina 27709; and the Department of Pharmacology and Cancer Biology, Duke University Medical School (J.D.N., B.L.W., I.A., D.P.M.), Durham, North Carolina 27710

Address all correspondence and requests for reprints to: Dr. D. P. McDonnell, Department of Pharmacology and Cancer Biology, Box 3813, Duke University Medical School, Durham, North Carolina 27710. E-mail: McDon016{at}acpub.duke.edu

The estrogen receptor (ER) mixed agonists tamoxifen and raloxifene have been shown to protect against bone loss in ovariectomized rats. However, the mechanism by which these compounds manifest their activity in bone is unknown. We have used a series of in vitro screens to select for compounds that are mechanistically distinct from tamoxifen and raloxifene in an effort to define the properties of an ER modulator required for bone protection. Using this approach, we identified a novel high affinity ER antagonist, GW5638, which when assayed in vitro functions as an ER antagonist, inhibiting the agonist activity of estrogen, tamoxifen, and raloxifene and reversing the "inverse agonist" activity of the pure antiestrogen ICI182,780. Thus, GW5638 appears to function as an antagonist in these in vitro systems, although in a manner distinct from other known ER modulators. Predictably, therefore, GW5638 alone displays minimal uterotropic activity in ovariectomized rats, but will inhibit the agonist activity of estradiol in this environment. Unexpectedly, however, this compound functions as a full ER agonist in bone and the cardiovascular system. These data suggest that the mechanism by which ER operates in different cells is not identical, and that classical agonist activity is not required for the bone protective activity of ER modulators.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. M. Wittmann, A. Sherk, and D. P. McDonnell
Definition of Functionally Important Mechanistic Differences among Selective Estrogen Receptor Down-regulators
Cancer Res., October 1, 2007; 67(19): 9549 - 9560.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J. H. Kim, M. H. Lee, B. J. Kim, J. H. Kim, S. J. Han, H. Y. Kim, and M. R Stallcup
Role of aspartate 351 in transactivation and active conformation of estrogen receptor {alpha}
J. Mol. Endocrinol., December 1, 2005; 35(3): 449 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. P. McDonnell
The Molecular Pharmacology of Estrogen Receptor Modulators: Implications for the Treatment of Breast Cancer
Clin. Cancer Res., January 15, 2005; 11(2): 871s - 877s.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. Shao, E. K. Keeton, D. P. McDonnell, and M. Brown
Coactivator AIB1 links estrogen receptor transcriptional activity and stability
PNAS, August 10, 2004; 101(32): 11599 - 11604.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. A. Iannone, C. A. Simmons, S. H. Kadwell, D. L. Svoboda, D. E. Vanderwall, S.-J. Deng, T. G. Consler, J. Shearin, J. G. Gray, and K. H. Pearce
Correlation between in Vitro Peptide Binding Profiles and Cellular Activities for Estrogen Receptor-Modulating Compounds
Mol. Endocrinol., May 1, 2004; 18(5): 1064 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. M. Hall and K. S. Korach
Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer Cells
Mol. Endocrinol., May 1, 2003; 17(5): 792 - 803.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Webb, P. Nguyen, and P. J. Kushner
Differential SERM Effects on Corepressor Binding Dictate ERalpha Activity in Vivo
J. Biol. Chem., February 21, 2003; 278(9): 6912 - 6920.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. J. Ho and J. K. Liao
Nonnuclear Actions of Estrogen
Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1952 - 1961.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Levenson, K. M. Svoboda, K. M. Pease, S. A. Kaiser, B. Chen, L. A. Simons, B. D. Jovanovic, P. A. Dyck, and V. C. Jordan
Gene Expression Profiles with Activation of the Estrogen Receptor {alpha}-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor
Cancer Res., August 1, 2002; 62(15): 4419 - 4426.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. C. Dardes, R. M. O'Regan, C. Gajdos, S. P. Robinson, D. Bentrem, A. De Los Reyes, and V. C. Jordan
Effects of a New Clinically Relevant Antiestrogen (GW5638) Related to Tamoxifen on Breast and Endometrial Cancer Growth in Vivo
Clin. Cancer Res., June 1, 2002; 8(6): 1995 - 2001.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
D. P. McDonnell, C. E. Connor, A. Wijayaratne, C.-y. Chang, and J. D. Norris
Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators
Recent Prog. Horm. Res., January 1, 2002; 57(1): 295 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. E. Connor, J. D. Norris, G. Broadwater, T. M. Willson, M. M. Gottardis, M. W. Dewhirst, and D. P. McDonnell
Circumventing Tamoxifen Resistance in Breast Cancers Using Antiestrogens That Induce Unique Conformational Changes in the Estrogen Receptor
Cancer Res., April 1, 2001; 61(7): 2917 - 2922.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. J. Bentrem, R. C. Dardes, H. Liu, J. MacGregor-Schafer, J. W. Zapf, and V. C. Jordan
Molecular Mechanism of Action at Estrogen Receptor {{alpha}} of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen
Endocrinology, February 1, 2001; 142(2): 838 - 846.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Dutertre and C. L. Smith
Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 431 - 437.
[Abstract] [Full Text]

Home page
 JCOHome page
C. K. Osborne and S. A. W. Fuqua
Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
R. B. Dickson and G. M. Stancel
Chapter 8: Estrogen Receptor-Mediated Processes in Normal and Cancer Cells
J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 135 - 145.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. Fuse, H. Kitagawa, and S. Kato
Characterization of Transactivational Property and Coactivator Mediation of Rat Mineralocorticoid Receptor Activation Function-1 (AF-1)
Mol. Endocrinol., June 1, 2000; 14(6): 889 - 899.
[Abstract] [Full Text]

Home page
 Toxicol PatholHome page
J. Ashby
Validation of In Vitro and In Vivo Methods for Assessing Endocrine Disrupting Chemicals
Toxicol Pathol, May 1, 2000; 28(3): 432 - 437.
[Abstract] [PDF]

Home page
 EndocrinologyHome page
Q. Qu, H. Zheng, J. Dahllund, A. Laine, N. Cockcroft, Z. Peng, M. Koskinen, K. Hemminki, L. Kangas, K. Vaananen, et al.
Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats
Endocrinology, February 1, 2000; 141(2): 809 - 820.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. M. Hall and D. P. McDonnell
The Estrogen Receptor {beta}-Isoform (ER{beta}) of the Human Estrogen Receptor Modulates ER{alpha} Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens
Endocrinology, December 1, 1999; 140(12): 5566 - 5578.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
A. L. Wijayaratne, S. C. Nagel, L. A. Paige, D. J. Christensen, J. D. Norris, D. M. Fowlkes, and D. P. McDonnell
Comparative Analyses of Mechanistic Differences Among Antiestrogens
Endocrinology, December 1, 1999; 140(12): 5828 - 5840.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
P. Webb, P. Nguyen, C. Valentine, G. N. Lopez, G. R. Kwok, E. McInerney, B. S. Katzenellenbogen, E. Enmark, J.-A. Gustafsson, S. Nilsson, et al.
The Estrogen Receptor Enhances AP-1 Activity by Two Distinct Mechanisms with Different Requirements for Receptor Transactivation Functions
Mol. Endocrinol., October 1, 1999; 13(10): 1672 - 1685.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
M. E. Nuttall, J. N. Bradbeer, G. B. Stroup, D. P. Nadeau, S. J. Hoffman, H. Zhao, S. Rehm, and M. Gowen
Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats
Endocrinology, December 1, 1998; 139(12): 5224 - 5234.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Sato, G. Q. Zeng, E. Rowley, and C. H. Turner
LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34)
Endocrinology, November 1, 1998; 139(11): 4642 - 4651.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Sato, C. H. Turner, T. Wang, M. D. Adrian, E. Rowley, and H. U. Bryant
LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 1 - 7.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society